Amgen’s New Enbrel Patent May Undercut Health Care Plan
Amgen s New Enbrel Patent May Undercut Health Care Plan
The extra patent protection of the profitable drug Enbrel, a rheumatoid arthritis and psoriasis treatment, could keep a cheaper version off the market until 2028.